Solana Company (NASDAQ: HSDT) Announces Executive Departure and Files 8-K with SEC
April 13, 2026 — Solana Company (NASDAQ: HSDT), a Delaware-incorporated firm specializing in finance services and crypto assets, has filed a Form 8-K with the Securities and Exchange Commission (SEC) regarding the recent departure of a key executive. This filing includes the disclosure of a significant separation agreement, which could have material implications for shareholders and may influence the company’s share price.
Key Points from the SEC Filing
- Executive Departure: The company announced the separation of Antonella Favit-Van Pelt, effective April 8, 2026. Her departure was formalized through a separation agreement, the material terms of which were included as an exhibit in the 8-K filing.
- Separation Agreement: The agreement details the terms under which Ms. Favit-Van Pelt left the company, including the vesting of equity awards and waivers of certain rights.
- No Simultaneous Written, Soliciting, or Tender Offer Communications: The company clarified in the filing that this 8-K is not being used for written communications under Rule 425, soliciting material under Rule 14a-12, or pre-commencement tender offers under Rules 14d-2(b) or 13e-4(c).
- Financial Statements and Exhibits: The company attached the full text of the separation agreement as Exhibit 10.1 and included the Cover Page Interactive Data File as Exhibit 104.
Details of the Separation Agreement
- Equity Vesting: Ms. Favit-Van Pelt will only be considered vested in stock options up to her separation date of April 8, 2026. She acknowledges that her rights to purchase shares and exercise options are limited to what was vested by that date, with all other unvested options forfeited.
- Release of Claims: The agreement contains a comprehensive release by the departing executive, waiving any and all claims related to her employment and termination, including claims regarding her stock options, wrongful discharge, breach of contract, and more.
- Cooperation Clause: Ms. Favit-Van Pelt agreed to cooperate with the company in any ongoing or future investigations, disputes, or claims related to her employment, including testifying if necessary.
- Non-Disparagement: The agreement includes a non-disparagement clause, prohibiting the former executive from making any defamatory or disparaging remarks about the company.
- Waiver of Statutory Inspection Rights: Importantly, Ms. Favit-Van Pelt waives her rights under Section 220 of the Delaware General Corporation Law (and similar laws) to inspect the company’s stock ledger or other corporate records in her capacity as a shareholder or option holder.
- Costs: Each party will bear its own legal and other costs related to the preparation of the agreement.
- No Representations: The departing executive represents that she has not relied on any representations not included in the agreement and has had the opportunity to consult legal counsel.
- Signatories: The agreement was signed on behalf of Solana Company by CEO Dane Andreeff on April 8, 2026.
Potential Implications for Shareholders and Share Price
- Leadership Change: The departure of a senior executive, especially one with equity and contractual rights, can signal shifts in company strategy, management priorities, or internal dynamics. Such changes can impact investor confidence and may be seen as a risk or opportunity depending on the context and Ms. Favit-Van Pelt’s role and contributions.
- Equity and Dilution Impact: By limiting the vesting of stock options to the separation date and waiving rights to further equity, the agreement potentially reduces future dilution risk for existing shareholders.
- No Ongoing Legal Exposure: The comprehensive release of claims and cooperation clause lowers the risk of future litigation or disputes involving the former executive, which can be reassuring to investors.
- No Emerging Growth Company Status: The filing states that Solana Company is not classified as an “emerging growth company,” which may affect its regulatory obligations and market perceptions.
Other Notable Information
- Ticker Symbol: HSDT
- Exchange: Nasdaq Stock Market LLC
- Business Address: 642 Newtown Yardley Road, Newtown, PA 18940
- EIN: 36-4787690
- Former Name: Helius Medical Technologies, Inc. (name changed in 2018)
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors are encouraged to review the full SEC filing and consult with their financial adviser before making investment decisions. Past performance is not indicative of future results. The departure of executives and related agreements may have unforeseen effects on company operations, governance, and share value.
View Solana Co Historical chart here
